• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea.在韩国使用大型真实世界临床数据比较SGLT2抑制剂与DPP4抑制剂和磺脲类药物作为2型糖尿病二线治疗的心血管安全性
Diabetes Metab J. 2021 Jul;45(4):502-504. doi: 10.4093/dmj.2021.0158. Epub 2021 Jul 30.
2
Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶 4 抑制剂和磺脲类药物治疗糖尿病酮症酸中毒的安全性比较。
Diabetes Care. 2022 Apr 1;45(4):919-927. doi: 10.2337/dc21-2177.
3
Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.二肽基肽酶-4抑制剂与2型糖尿病患者心力衰竭风险：一项基于人群的队列研究。
Circ Heart Fail. 2017 Sep;10(9). doi: 10.1161/CIRCHEARTFAILURE.117.003957.
4
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus.钠-葡萄糖共转运蛋白 2 抑制剂作为 2 型糖尿病患者二甲双胍单药治疗的附加药物的心血管安全性。
Diabetes Metab J. 2021 Jul;45(4):505-514. doi: 10.4093/dmj.2020.0057. Epub 2020 Oct 30.
5
Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.SGLT2 抑制剂、GLP-1 受体激动剂、DPP-4 抑制剂和磺脲类药物在肾脏结局风险方面的比较效果：使用医疗保健数据库模拟目标试验。
Diabetes Care. 2020 Nov;43(11):2859-2869. doi: 10.2337/dc20-1890. Epub 2020 Sep 16.
6
Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.在2型糖尿病胰岛素治疗中添加钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂与二肽基肽酶4（DPP4）抑制剂的比较：一项采用间接比较荟萃分析的系统评价
Diabetes Metab Res Rev. 2017 Jan;33(1). doi: 10.1002/dmrr.2818. Epub 2016 Jun 8.
7
Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes.二肽基肽酶-4 抑制剂与磺脲类药物和其他降糖疗法治疗三种急性结局的比较安全性。
Sci Rep. 2018 Oct 11;8(1):15142. doi: 10.1038/s41598-018-33483-y.
8
Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.2 型糖尿病的二线降糖治疗。
Curr Diab Rep. 2019 Jul 8;19(8):54. doi: 10.1007/s11892-019-1171-0.
9
Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的心血管结局。
Diabetes Obes Metab. 2019 Jan;21(1):28-36. doi: 10.1111/dom.13477. Epub 2018 Aug 16.
10
Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.钠-葡萄糖共转运蛋白 2 抑制剂与尿路感染：基于倾向评分匹配的人群队列研究。
Can J Diabetes. 2022 Jun;46(4):392-403.e13. doi: 10.1016/j.jcjd.2021.12.005. Epub 2021 Dec 30.

引用本文的文献

1
Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis.糖尿病患者中与钠-葡萄糖协同转运蛋白抑制剂（SGLT抑制剂）和二肽基肽酶-4抑制剂（DPP-4抑制剂）相关的癌症比较风险：一项系统评价和荟萃分析
Diabetol Metab Syndr. 2025 Aug 7;17(1):321. doi: 10.1186/s13098-025-01898-z.
2
The neuroprotective potential of phytochemicals in traumatic brain injury: mechanistic insights and pharmacological implications.植物化学物质在创伤性脑损伤中的神经保护潜力：机制见解与药理学意义
Front Pharmacol. 2024 Jan 4;14:1330098. doi: 10.3389/fphar.2023.1330098. eCollection 2023.

本文引用的文献

1
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.《2017年美国心脏病学会（ACC）心力衰竭治疗优化专家共识决策路径2021年更新：关于射血分数降低的心力衰竭的10个关键问题解答：美国心脏病学会解决方案集监督委员会报告》
J Am Coll Cardiol. 2021 Feb 16;77(6):772-810. doi: 10.1016/j.jacc.2020.11.022. Epub 2021 Jan 11.
2
9. Pharmacologic Approaches to Glycemic Treatment: .9. 血糖治疗的药物学方法： 。
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124. doi: 10.2337/dc21-S009.
3
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus.钠-葡萄糖共转运蛋白 2 抑制剂作为 2 型糖尿病患者二甲双胍单药治疗的附加药物的心血管安全性。
Diabetes Metab J. 2021 Jul;45(4):505-514. doi: 10.4093/dmj.2020.0057. Epub 2020 Oct 30.
4
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
5
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.达格列净治疗射血分数降低的心力衰竭患者。
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
6
2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea.2019 年韩国 2 型糖尿病临床实践指南。
Diabetes Metab J. 2019 Aug;43(4):398-406. doi: 10.4093/dmj.2019.0137.
7
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
8
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.达格列净与 2 型糖尿病患者的心血管结局
N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.
9
When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.当二甲双胍不够用时：SGLT2 和 DPP-4 抑制剂作为二线治疗的优缺点。
Diabetes Metab Res Rev. 2018 May;34(4):e2981. doi: 10.1002/dmrr.2981. Epub 2018 Feb 15.
10
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.

Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea.

作者信息

Kim Kyuho, Choi Sung Hee

机构信息

Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

出版信息

Diabetes Metab J. 2021 Jul;45(4):502-504. doi: 10.4093/dmj.2021.0158. Epub 2021 Jul 30.

DOI:10.4093/dmj.2021.0158
PMID:34352987
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8369211/
Abstract
摘要